Evidence map›Paper›PMID 37906419›Full record

ArticleEuropean journal of epidemiology2024

Habitual coffee consumption and risk of dementia in older persons: modulation by CYP1A2 polymorphism.

Sophie Lefèvre-Arbogast, Catherine Helmer, Claudine Berr, Stéphanie Debette, Cécilia Samieri

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European journal of epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Nutrition: A non-negligible factor in the pathogenesis and treatment of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sophie Lefèvre-ArbogastUniversity of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, 146 Rue Léo-Saignat, Bordeaux Cedex, 33076, France. Sophie.Lefevre-Arbogast@u-bordeaux.fr.ORCID http://orcid.org/0000-0002-7857-6697
Catherine HelmerUniversity of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, 146 Rue Léo-Saignat, Bordeaux Cedex, 33076, France.
Claudine BerrUniversity of Montpellier, Institute for Neurosciences of Montpellier, Inserm, UMR 1298, Montpellier, 34091, France.
Stéphanie DebetteUniversity of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, 146 Rue Léo-Saignat, Bordeaux Cedex, 33076, France.
Cécilia SamieriUniversity of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, 146 Rue Léo-Saignat, Bordeaux Cedex, 33076, France.
Université de Bordeaux · FRInserm · FR

Funding

Agence Nationale de la Recherche COGINUT ANR-06-PNRA-005
6 · The paper itself

Abstract

Higher coffee consumption has been associated with reduced dementia risk, yet with inconsistencies across studies. CYP1A2 polymorphisms, which affects caffeine metabolism, may modulate the association between coffee and the risk of dementia and Alzheimer's disease (AD). We included 5964 participants of the Three-City Study (mean age 74 years-old), free of dementia at baseline when they reported their daily coffee consumption, with available genome-wide genotyping and followed for dementia over a median of 9.0 (range 0.8-18.7) years. In Cox proportional-hazards models, the relationship between coffee consumption and dementia risk was modified by CYP1A2 polymorphism at rs762551 (p for interaction = 0.034). In multivariable-adjusted models, coffee intake was linearly associated with a decreased risk of dementia among carriers of the C allele only ("slower caffeine metabolizers"; HR for 1-cup increased [95% CI] 0.90 [0.83-0.97]), while in non-carriers ("faster caffeine metabolizers"), there was no significant association but a J-shaped trend toward a decrease in dementia risk up to 3 cups/day and increased risk beyond. Thus, compared to null intake, drinking ≥ 4 cups of coffee daily was associated with a reduced dementia risk in slower but not faster metabolizers (HR [95% CI] for ≥ 4 vs. 0 cup/day = 0.45 [0.25-0.80] and 1.32 [0.89-1.96], respectively). Results were similar when studying AD and another CYP1A2 candidate polymorphism (rs2472304), but no interaction was found with CYP1A2 rs2472297 or rs2470893. In this cohort, a linear association of coffee intake to lower dementia risk was apparent only among carriers of CYP1A2 polymorphisms predisposing to slower caffeine metabolism.

Indexed as

CoffeeCytochrome P-450 CYP1A2DementiaAgedCaffeineHumansRisk FactorsCaffeineCoffeeCYP1A2 protein, humanCytochrome P-450 CYP1A2Alzheimer’s diseaseCaffeineCoffeeCYP1A2Dementia

Identifiers

PMID37906419
OpenAlexW4388048857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.